What does AusperBio do?
AusperBio is a San Francisco and Hangzhou-based clinical-stage biotechnology company dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies across a range of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases.
How much did they raise?
The company raised $50M in a Series B+ round led by an undisclosed investor, with participation from Qiming Venture Partners, CDH Investments, Genesis Capital, YuanBio Venture Capital, HanKang Capital, and Sherpa Capital. This follows their previous Series B round completed in December 2024.
What are their plans for the money?
AusperBio plans to use the funds to support the ongoing clinical development of AHB-137, a novel unconjugated antisense oligonucleotide, including planned Phase II trials outside of mainland China, potentially advancing the goal of a functional cure for chronic hepatitis B.
What have they achieved so far?
The company has already made progress with its proprietary Med-Oligo ASO platform, which has demonstrated significant enhancements over current antisense therapeutics through innovative ASO design and targeted delivery conjugation technologies.
